Natural History of Rare Tumor Risk Syndromes: A Scoping Review to Inform Cost-Effectiveness Models

Di Fabrizio Carolina; Gonçalves Judite; R. Shabuz Zillur; Andrew Titman; Paula Boaventura; Svetlana Bajalica Lagercrantz; Barbara Peleteiro; Sara Pereira; Liliana Sousa; Stefan Aretz; Paula Soares; Schuurs Hoeijmakers Janneke; Christophe Thery Jean; Hoberg Vetti Hildegunn; Balmaña Judith; Joan Brunet; Carla Oliveira; Céu Mateus; on behalf of PREVENTABLE Consortium

doi:10.5281/zenodo.23419623

Abstract

This scoping review maps the available evidence on the natural history, cancer risk, and surveillance strategies in selected Rare Tumour Risk Syndromes (RTRS) to inform disease progression models and future economic evaluations

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Carolina et al. (2026) studied this question.

synapsesocial.com/papers/6ad461b28f57aa2f197e91d2 https://doi.org/10.5281/zenodo.23419623

View Full Paper

Ask AI

Bookmark

Share

Natural History of Rare Tumor Risk Syndromes: A Scoping Review to Inform Cost-Effectiveness Models

Abstract

Discussion

Cite This Study

Natural History of Rare Tumor Risk Syndromes: A Scoping Review to Inform Cost-Effectiveness Models

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Journal of health economics and outcomes research

Keep reading

More related papers

More from Journal of health economics and outcomes research